- Home
- BCTX vs KXIN Comparison
BCTX vs KXIN Comparison
Compare BCTX & KXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- KXIN
- Stock Information
- Founded
- BCTX 2014
- KXIN 2015
- Country
- BCTX Canada
- KXIN China
- Employees
- BCTX N/A
- KXIN N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- KXIN Retail-Auto Dealers and Gas Stations
- Sector
- BCTX Health Care
- KXIN Consumer Discretionary
- Exchange
- BCTX Nasdaq
- KXIN Nasdaq
- Market Cap
- BCTX 16.1M
- KXIN 13.0M
- IPO Year
- BCTX N/A
- KXIN N/A
- Fundamental
- Price
- BCTX $3.41
- KXIN $0.95
- Analyst Decision
- BCTX Strong Buy
- KXIN
- Analyst Count
- BCTX 1
- KXIN 0
- Target Price
- BCTX $32.00
- KXIN N/A
- AVG Volume (30 Days)
- BCTX 791.2K
- KXIN 208.5K
- Earning Date
- BCTX 06-13-2025
- KXIN 01-01-0001
- Dividend Yield
- BCTX N/A
- KXIN N/A
- EPS Growth
- BCTX N/A
- KXIN N/A
- EPS
- BCTX N/A
- KXIN N/A
- Revenue
- BCTX N/A
- KXIN N/A
- Revenue This Year
- BCTX N/A
- KXIN N/A
- Revenue Next Year
- BCTX N/A
- KXIN N/A
- P/E Ratio
- BCTX N/A
- KXIN N/A
- Revenue Growth
- BCTX N/A
- KXIN N/A
- 52 Week Low
- BCTX $2.81
- KXIN $0.64
- 52 Week High
- BCTX $29.40
- KXIN $29.54
- Technical
- Relative Strength Index (RSI)
- BCTX 47.56
- KXIN 48.40
- Support Level
- BCTX $2.81
- KXIN $0.91
- Resistance Level
- BCTX $3.69
- KXIN $1.02
- Average True Range (ATR)
- BCTX 0.28
- KXIN 0.06
- MACD
- BCTX 0.06
- KXIN -0.00
- Stochastic Oscillator
- BCTX 65.93
- KXIN 20.66
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About KXIN Kaixin Auto Holdings
Kaixin Holdings is an auto retail platform for luxury used cars and imported new cars. The company is actively engaged in the research and development, design, manufacturing, and sales of electric vehicles and promotes the innovation of next-generation autonomous driving and artificial intelligence technologies. The company generates revenues from sales of used cars, as well as fees obtained from its role as a channel partner for third-party auto financing and other value-added service providers.